Early intravenous beta-blockers in patients with acute coronary syndrome--a meta-analysis of randomized trials.

ABSTRACT:

Background

Intravenous (IV) beta-blockade is currently a Class IIa recommendation in early management of patients with acute coronary syndromes (ACS) without obvious contraindications.

Methods

We searched the PubMed, EMBASE and the Cochrane Register for Controlled Clinical Trials for randomized clinical trials from 1965 through December, 2011, comparing intravenous beta-blockers administered within 12 hours of presentation of ACS with standard medical therapy and/or placebo. The primary outcome assessed was the risk of short-term (in-hospital mortality-with maximum follow up duration of 90 days) all-cause mortality in the intervention group versus the comparator group. The secondary outcomes assessed were ventricular tachyarrhythmias, myocardial reinfarction, cardiogenic sho

SUBMITTER: Chatterjee S 

PROVIDER: S-EPMC4104797 | biostudies-literature | 2013 Sep

REPOSITORIES: biostudies-literature